# US 2002/0001828 A1 · Chemokine-like factors (CKLFs) with chemotactic and hematopoietic stimulating activities

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0001828 A1
- Document ID: US20020001828A1
- Status: Published application
- Kind: A1
- Application number: 09/801,115
- Filed: 2001-03-07
- Published: 2002-01-03
- Earliest claimed: 1999-05-14
- Assignees: Beijing Medical University; Beijing Medical University United Biological Engineering Company
- Inventors: Dalong Ma; Wenling Han; Yingmei Zhang; Quansheng Song; Chunhui Di; Jiaqiang Huang; Jian Tang; Guanghui Chen
- Web page: https://patentgrep.com/patent/US20020001828A1

## CPC

- C07K 14/521: {Chemokines}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides chemokine-like factor (CKLF) polypeptides with chemotactic and hematopoietic stimulating activities and polynucleotides encoding such polypeptides. Additionally, a method for producing such CKLF polypeptides by recombinant techniques is provided. Also provided are the antibodies and antagonists against such polypeptides. The present invention further disclose a drug compound comprising a therapeutically effective amount of such CKLF polypeptides as well as pharmaceutically acceptable excipients and carriers. Also disclosed are the uses of such CKLF polypeptides and polynucleotides in diagnostics or therapeutics to treat immunodeficiency, hematopoietic diseases and primary tumors.

## Claims

### Claim 1

An isolated polynucleotide comprising a member selected from the group consisting of:
(a) a polynucleotide encoding the polypeptide as set forth in SEQ ID NO:2;
(b) a polynucleotide encoding a mature polypeptide having the amino acid sequence expressed by the cDNA contained in CGMCC Deposit NO.0392;
(c) a polynucleotide encoding the polypeptide as set forth in SEQ ID NO:4;
(d) a polynucleotide encoding the polypeptide as set forth in SEQ ID NO:6;
(e) a polynucleotide encoding the polypeptide as set forth in SEQ ID NO:8;
(f) a naturally occurring variant of the polynucleotide of (a), (b), (c), (d) or (e);
(g) a polynucleotide capable of hybridizing to the polynucleotide of (a) or (b); and
(h) a polynucleotide which is at least 85% identical to the polynucleotide of (a) or (b).

### Claim 2 (depends on 1)

The polynucleotide of claim 1 wherein the polynucleotide is cDNA.

### Claim 3 (depends on 1)

The polynucleotide of claim 1 wherein the polynucleotide is RNA.

### Claim 4 (depends on 1)

The polynucleotide of claim 1 wherein the polynucleotide is genomic DNA.

### Claim 5 (depends on 1)

The polynucleotide of claim 1 having the sequence as set forth in SEQ ID NO:1.

### Claim 6 (depends on 1)

The polynucleotide of claim 1 having the sequence as set forth in SEQ ID NO:3.

### Claim 7 (depends on 1)

The polynucleotide of claim 1 having the sequence as set forth in SEQ ID NO:5.

### Claim 8 (depends on 1)

The polynucleotide of claim 1 having the sequence as set forth in SEQ ID NO:7.

### Claim 9 (depends on 2)

The polynucleotide of claim 2 encoding the polypeptide as set forth in SEQ ID NO:2.

### Claim 10 (depends on 2)

The polynucleotide of claim 2 encoding a mature polypeptide having the amino acid sequence expressed by the DNA contained in CGMCC Deposit NO.0392.

### Claim 11 (depends on 2)

The polynucleotide of claim 2 encoding the polypeptide as set forth in SEQ ID NO:4.

### Claim 12 (depends on 2)

The polynucleotide of claim 2 encoding the polypeptide as set forth in SEQ ID NO:6.

### Claim 13 (depends on 2)

The polynucleotide of claim 2 encoding the polypeptide as set forth in SEQ ID NO:8.

### Claim 14 (depends on 2)

A vector containing the cDNA of claim 2.

### Claim 15 (depends on 14)

A host cell transformed, transducted or transfected with the vector of claim 14.

### Claim 16 (depends on 14)

A method of producing a chemokine-like factor polypeptide comprising introducing a vector of claim 14 into a host cell, and expressing from the host cell or extracellular media the polypeptide encoded by said cDNA.

### Claim 17

A polypeptide comprising a member selected from the group consisting of:
(a) a polypeptide having the deduced amino acid sequence of SEQ ID NO:2;
(b) a polypeptide having the amino acid sequence encoded by the cDNA of CGMCC deposit NO.0392;
(c) a polypeptide having the deduced amino acid sequence of SEQ ID NO:4;
(d) a polypeptide having the deduced amino acid sequence of SEQ ID NO:6;
(e) a polypeptide having the deduced amino acid sequence of SEQ ID NO:8; and
(f) naturally occurring variants, analogs and derivatives of the polypeptides of (a), (b), (c), (d) and (e).

### Claim 18 (depends on 17)

The polypeptide of claim 17 having the amino acid sequence of SEQ ID NO:2.

### Claim 19 (depends on 17)

The polypeptide of claim 17 having the amino acid sequence encoded by the cDNA of CGMCC deposit NO.0392.

### Claim 20 (depends on 17)

The polypeptide of claim 17 having the amino acid sequence of SEQ ID NO:4.

### Claim 21 (depends on 17)

The polypeptide of claim 17 having the amino acid sequence of SEQ ID NO:6.

### Claim 22 (depends on 17)

The polypeptide of claim 17 having the amino acid sequence of SEQ ID NO:8.

### Claim 23 (depends on 17)

An antibody of the polypeptide of claim 17.

### Claim 24 (depends on 17)

A compound which inhibits activation of the polypeptide of claim 17.

### Claim 25 (depends on 17)

A method of using the CKLF1 polypeptide of claim 17 in the preparation of immunological adjuvants which can improve the curative effect of a DNA vaccine or a DNA drug.

### Claim 26 (depends on 17)

A method for the treatment of a patient having need of the CKLF polypeptide comprising administering to said patient a therapeutically effective amount of the polypeptide of claim 17.

### Claim 27 (depends on 26)

The method of claim 26 wherein said therapeutically effective amount of the polypeptide is administered by providing to the patient DNA encoding said polypeptide and expressing said polypeptide in vivo.

### Claim 28 (depends on 1)

A method of diagnosing a disease or a susceptibility to a disease comprising determining a mutation in the polynucleotide of claim 1.

### Claim 29 (depends on 17)

A diagnostic method comprising analyzing for the presence of the polypeptide of claim 17 in a sample derived from a host.

### Claim 30 (depends on 28)

The method of claim 28 wherein said disease comprises inflammations, degenerative diseases, primary tumors and hematopoietic disorders.

### Claim 31 (depends on 30)

The method of claim 30 wherein said inflammations comprise rheumatoid arthritis and other autoimmune diseases, allergies and hyperplastic diseases.

### Claim 32 (depends on 30)

The method of claim 30 wherein said degenerative diseases comprise muscular dystrophy and hair loss.

### Claim 33 (depends on 30)

The method of claim 30 wherein said tumors are selected from the group consisting of breast cancer, colon cancer, lung cancer, ovarian cancer, pancreatic cancer and prostate cancer.
